Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin receptor imaging.

Dik J Kwekkeboom1, Eric P Krenning

  • 1Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.

Seminars in Nuclear Medicine
|April 20, 2002
PubMed
Summary

[(111)In-DTPA(0)]octreotide is a radiopharmaceutical for visualizing somatostatin receptor-positive tumors. Somatostatin Receptor Imaging (SRI) effectively localizes neuroendocrine tumors and may benefit Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [<sup>177</sup>Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.

Cancer medicine·2025
Same author

Reshaping [<sup>99m</sup>Tc]Tc-DT11 to DT14D Tagged with Trivalent Radiometals for NTS<sub>1</sub>R-Positive Cancer Theranostics.

Pharmaceutics·2025
Same author

Diagnosis of Prostate Cancer with a Neurotensin-Bombesin Radioligand Combination-First Preclinical Results.

Pharmaceutics·2024
Same author

Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile.

International journal of molecular sciences·2024
Same author

Side-Chain Modified [<sup>99m</sup>Tc]Tc-DT1 Mimics: A Comparative Study in NTS<sub>1</sub>R-Positive Models.

International journal of molecular sciences·2023

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmacology

Background:

  • [(111)In-DTPA(0)]octreotide is a radiopharmaceutical with potential for visualizing somatostatin receptor-positive tumors.
  • Somatostatin Receptor Imaging (SRI) demonstrates high sensitivity in localizing neuroendocrine tumors.

Purpose of the Study:

  • To evaluate the utility of SRI in the localization and staging of various tumor types.
  • To explore the cost-effectiveness, patient management, and quality of life benefits of incorporating SRI.

Main Methods:

  • Utilizes [(111)In-DTPA(0)]octreotide for imaging.
  • Applies Somatostatin Receptor Imaging (SRI) techniques.

Main Results:

  • SRI shows high sensitivity for neuroendocrine tumor localization.
  • SRI can be beneficial in staging neuroendocrine tumors and Hodgkin's disease.
  • The value of SRI in breast cancer and granulomatous diseases requires further investigation.

Conclusions:

  • SRI is a valuable tool for specific tumor types, improving patient management and quality of life.
  • Further research is needed to establish SRI's role in other conditions.
  • Advancements in Peptide Receptor Radionuclide Therapy (PRRT) are anticipated to drive growth in peptide receptor imaging.

Related Experiment Videos